Learn More
OBJECTIVES When evaluating the pharmacodynamics of antimicrobials, assumptions are often made relative to their pharmacokinetics. One example of this is applying tissue penetration results of uninfected hosts to those displaying a targeted illness. As tigecycline evolves into a potential treatment option for pneumonia, we determined whether the presence of(More)
Voriconazole and anidulafungin in combination are being investigated for use for the treatment of pulmonary aspergillosis. We determined the pulmonary disposition of these agents. Twenty healthy participants received intravenous voriconazole (at 6 mg/kg of body weight every 12 h [q12h] on day 1 and then at 4 mg/kg q12h) and anidulafungin (200 mg on day 1(More)
INTRODUCTION We aimed to describe the in vivo efficacy of meropenem, in addition to cefepime and levofloxacin as comparators against VIM-producing Pseudomonas aeruginosa and compare the findings to our previous observations with Enterobacteriaceae. METHODS Eight clinical P. aeruginosa isolates with meropenem MICs from 4 to 512 mg/L were studied in a(More)
• After confirmatory extended spectrum β-lactamase (ESBL) testing, 38% of strains identified as potential ESBL producers using a simple minimum inhibitory concentration (MIC) screen were excluded. • For agents with potential activity against ESBLs, such as ceftolozane/tazobactam, piperacillin/tazobactam, ertapenem, and meropenem, reduced susceptibility was(More)
We evaluated the in vitro potency of cefepime combined with AAI101, a novel extended-spectrum β-lactamase inhibitor, against a population of clinical Escherichia coli and Klebsiella pneumoniae collected from USA hospitals. Of the 223 cefepime non-susceptible isolates, 95% were ceftazidime non-susceptible, 49% ertapenem non-susceptible, 57%(More)
  • 1